All material Copyright© 2008-2010 Rett Syndrome Research Trust
Reprinted with the express permission of Rett Syndrome Research Trust (RSRT) as originally published on their Website.
Mutations in a gene called MECP2 (methyl-CpG-binding protein 2) were identified as the cause of Rett Syndrome in 1999, in the laboratory of Huda Zoghbi, M.D. at Baylor College of Medicine. First discovered by Adrian Bird, Ph.D., in 1990, MECP2 produces a multi-functional protein, also called MeCP2, which regulates the activity of a host of other genes crucial to normal development.
With rare exceptions, Rett Syndrome is sporadic, rather than an inherited disorder that is passed on from one generation to the next. In most cases, the damaged copy of MECP2 can be traced to the paternal allele, the result of a random sperm mutation. The incidence of recurrence in a family is less than 1%.
While Rett Syndrome remains a clinical diagnosis, the link with MECP2 has made DNA testing and confirmation possible for affected individuals and their families. To date, approximately 95% of girls exhibiting Rett symptoms have one of the over 200 currently identified MECP2 mutations. Attempts to correlate specific mutations to symptoms have been challenging. Though a positive DNA test result yields a quick, definitive answer for concerned parents and physicians, it also predicts the inevitable, tragic clinical course for which treatments and cures are urgently needed.
Featured Organization: Rett Syndrome Research Trust (RSRT)
Rett Syndrome Research Trust is a 501©(3) nonprofit organization intensively focused on the development of treatments and cures for Rett Syndrome and related MECP2 disorders. The strength of the Trust is based on the guidance of founders and advisors who are largely responsible for the major advances in Rett research over the past decade.
Please support our contributing organizations and visit Rett Syndrome Research Trust